Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05595460 · ClinicalTrials.gov registry record · Phase 1
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
A Phase 1 study of SCLC,Extensive Stage, sponsored by RayzeBio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
- 15
- Study locations
NCT05595460: Recruiting Phase 1 study of SCLC,Extensive Stage, sponsored by RayzeBio.
NCT05595460 is a Phase 1 study of SCLC,Extensive Stage that is actively recruiting participants, run by RayzeBio. The registered enrollment target is 49 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (18% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05595460, a Phase 1 study of SCLC,Extensive Stage, is actively recruiting participants, sponsored by RayzeBio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
- 15
- Study locations
Study Summary
This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.
Primary Outcome
RP2D as determined by incidence rate of DLTs
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG RYZ101 Dose Level 1
- DRUG RYZ101 Dose Level 2
- DRUG RYZ101 Dose Level 3
- DRUG RYZ101 Dose Level -1
Study Locations (15)
Florida
- Research Facility - Jacksonville
- Research Facility - Miami
- Research Facility - Orlando
California
- Research Facility - Los Angeles
- Research Facility - San Francisco
Michigan
- Research Facility - Grand Rapids
- Research Facility - Troy
Iowa
- Research Facility - Iowa City
Kentucky
- Reserach Facility - Lexington
Minnesota
- Research Facility - Rochester
Missouri
- Research Facility - St Louis
Nebraska
- Research Facility - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2022-10-10 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
What NCT05595460 shows while recruiting
NCT05595460 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (18% lower).
The record links to 1 condition, with SCLC,Extensive Stage appearing as the primary indexed condition, and to 5 interventions - of which Atezolizumab is the first listed.
NCT05595460 lists 15 locations in 11 states (Florida, California, Michigan).
Frequently Asked Questions
What is clinical trial NCT05595460 about?
NCT05595460 is a clinical study titled "Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC". This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.
What is the current status of trial NCT05595460?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2022-10-10. Estimated completion is 2029-03.
What conditions does trial NCT05595460 study?
This clinical trial studies the following conditions: SCLC,Extensive Stage.
What interventions are being tested in trial NCT05595460?
The interventions under investigation include: Atezolizumab (DRUG), RYZ101 Dose Level 1 (DRUG), RYZ101 Dose Level 2 (DRUG), RYZ101 Dose Level 3 (DRUG), RYZ101 Dose Level -1 (DRUG).
Who is sponsoring clinical trial NCT05595460?
This trial is sponsored by RayzeBio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05595460 being conducted?
This trial has 15 study locations across California, Florida, Iowa, Kentucky, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05595460's enrollment target sits among peer trials
49 1017th of 2000 higher than 976 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI